CAJ | 학술논문

目的：探讨左氧氟沙星联合盐酸坦索络辛及宁泌泰治疗慢性前列腺炎的疗效。方法：2013年1月至2014年8月，应用前瞻性随机平行对照研究将355例慢性前列腺炎患者随机分成 A、B，C，D 4组， A 组：左氧氟沙星联合盐酸坦索罗辛及宁泌泰89例；B 组：左氧氟沙星和盐酸坦索罗辛88例；C 组：左氧氟沙星联合宁泌泰87例；D 组：左氧氟沙星91例。4种方法各治疗6周，记录治疗前后慢性前列腺炎症状指数（NIH －EPSI）评分及前列腺液白细胞数目，并且比较治疗前后4种疗法的疗效。结果：4组治疗前 NIH—CP-SI 评分及前列腺液白细胞数目等基线资料比较差异均无统计学意义（P ＞0．05）。A 组治疗前后 NIH －CPSI评分为（24．34±4．65）和（13．72±5．22）分；前列腺液白细胞数目为（15．34±3．34）个和（7．08＋2．26）个／HP，治疗前后比较差异均有统计学意义（P ＜0．01）。A 组与其他3组治疗后 NIH －CPSI 比较差异有统计学意义（P ＜0．01），而前列腺液白细胞计数比较差异无统计学意义（P ＞0．05）。4组患者均未报告不良事件。结论：左氧氟沙星联合盐酸坦索络辛及宁泌泰治疗慢性前列腺炎疗效满意，有良好的安全性和耐受性。
목적：탐토좌양불사성연합염산탄색락신급저비태치료만성전렬선염적료효。방법：2013년1월지2014년8월，응용전첨성수궤평행대조연구장355례만성전렬선염환자수궤분성 A、B，C，D 4조， A 조：좌양불사성연합염산탄색라신급저비태89례；B 조：좌양불사성화염산탄색라신88례；C 조：좌양불사성연합저비태87례；D 조：좌양불사성91례。4충방법각치료6주，기록치료전후만성전렬선염증상지수（NIH －EPSI）평분급전렬선액백세포수목，병차비교치료전후4충요법적료효。결과：4조치료전 NIH—CP-SI 평분급전렬선액백세포수목등기선자료비교차이균무통계학의의（P ＞0．05）。A 조치료전후 NIH －CPSI평분위（24．34±4．65）화（13．72±5．22）분；전렬선액백세포수목위（15．34±3．34）개화（7．08＋2．26）개／HP，치료전후비교차이균유통계학의의（P ＜0．01）。A 조여기타3조치료후 NIH －CPSI 비교차이유통계학의의（P ＜0．01），이전렬선액백세포계수비교차이무통계학의의（P ＞0．05）。4조환자균미보고불량사건。결론：좌양불사성연합염산탄색락신급저비태치료만성전렬선염료효만의，유량호적안전성화내수성。
Objectives:To evaluate the efficacy of Levofloxacin tablets combined with Tamsulosin and Ning-bitai for the treatment of chronic prostatitis.Methods:From January 201 3 to August 201 4,355 patients were in-cluded in this prospective study.All the 355 patients were randomly divided into 4 groups (A,B,C,D):89 pa-tients received Levofloxacin tablets combined with Tamsulosin and Ningbitai;88 patients received Levofloxacin tab-lets and Tamsulosin;87 patients were treated with Levofloxacin tablets and Ningbitai;91 patients were treated with Levofloxacin tablets only.NIH -chronic Prostatitis symptom index (NIH -CPSI)and white blood cell (WBC) counts in expressed prostate secretion (EPS)were evaluated before and 6 weeks after the treatment.The results of the four groups were compared.Results:Before the treatment,there was no significant difference in the (NIH -CPSI)and white blood cell (WBC)counts among the 4 groups.The NIH—CPSI (24.34 ±4.65 versus 1 3.72 ± 5.22)and EPS WBC count (9.75 ±2.24 versus 9.08 ±2.26)significantly decreased in group A after 6 weeks of treatment (P <0.01 ).The NIH -CPSI in group A after treatment was significantly lower than those in the other three groups (P <0.01 ),but there was no significant difference in EPS WBC count among the 4 groups (P >0.05).All patients in the 4 groups did not report diverse events.Conclusion:The use of levofloxacin tablets com-bined with tamsulosin and ningbitai can improve the symptoms for patients,which is safe and effective in the treat-ment of chronic prostatitis.